CG Oncology Inc. Common s...

NASDAQ: CGON · Real-Time Price · USD
25.74
-0.22 (-0.85%)
At close: Aug 15, 2025, 12:34 PM

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology Inc. Common stock
CG Oncology Inc. Common stock logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 113
CEO Arthur Kuan

Contact Details

Address:
400 Spectrum Center Drive
Irvine, Delaware
United States
Website https://cgoncology.com

Stock Details

Ticker Symbol CGON
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001991792
CUSIP Number 156944100
ISIN Number US1569441009
Employer ID 37-1611499
SIC Code 2836

Key Executives

Name Position
Arthur Kuan Chairman & Chief Executive Officer
Ambaw Bellete M.S. President & Chief Operating Officer
Corleen M. Roche Chief Financial Officer
Amy Steele Vice President of Finance, Accounting & Administration
Bing Kung Vice President of Corporate Development
Dr. Vijay Kasturi M.D. Chief Medical Officer
Joshua F. Patterson General Counsel, Chief Compliance Officer & Secretary
Sarah Connors Vice President of Communications & Patient Advocacy
Swapnil Bhargava Ph.D. Chief Technical Officer

Latest SEC Filings

Date Type Title
Aug 08, 2025 10-Q Quarterly Report
Aug 08, 2025 8-K Current Report
Aug 06, 2025 3 Filing
Aug 06, 2025 SCHEDULE 13G Filing
Jul 18, 2025 4 Filing
Jul 11, 2025 8-K Current Report
Jun 06, 2025 4 Filing
Jun 06, 2025 4 Filing
Jun 06, 2025 4 Filing
Jun 06, 2025 4 Filing